Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells $247,796.10 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Denali Therapeutics Stock Down 10.1 %

Denali Therapeutics stock opened at $19.10 on Friday. The business has a 50 day moving average price of $24.13 and a two-hundred day moving average price of $24.83. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -6.92 and a beta of 1.39. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) earnings per share. On average, analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DNLI. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday. Jefferies Financial Group upped their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday. HC Wainwright decreased their price target on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $31.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $38.91.

Hedge Funds Weigh In On Denali Therapeutics

Large investors have recently added to or reduced their stakes in the company. CWM LLC raised its holdings in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Denali Therapeutics in the 3rd quarter valued at approximately $73,000. Assetmark Inc. lifted its position in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Denali Therapeutics during the 2nd quarter worth approximately $194,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.